InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,270.13
(
-0.69%
)
US TECH 100
18,122.80
(
-0.58%
)
Dow Jones
39,098.33
(
-1.44%
)
Brent Oil
81.22
(
-0.38%
)
Bitcoin
67,097.18
(
-2.90%
)
Post# of 251908
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119681
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 228599

Thursday, 03/26/2020 5:32:53 PM

Thursday, March 26, 2020 5:32:53 PM

Post# of 251908
ABUS reports interim phase-1 data on AB-729 for HBV:

https://finance.yahoo.com/news/arbutus-announces-positive-preliminary-phase-200510591.html

AB-729 is an injected RNAi agent that targets HBsAg. The data reported today are from a single subcutaneous dose.

After 29 days, the mean reduction in HBsAg was: 0.2 logs in the 60mg cohort; and 0.8 logs in the 180mg cohort.

After 12 weeks, the mean reduction in HBsAg was: n/a in the 60mg cohort; and -1.0 logs in the 180mg cohort.

Whether HBsAg is the right target to be hitting is somewhat controversial—see, for instance, #msg-152274693.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up